Term
|
Definition
| oral antibiotics are a possibility: Ciprofloxacin + amoxicillin/Clavulanate |
|
|
Term
| Initial Regimen High Risk |
|
Definition
| IV antibiotics are needed: Monotherapy vs dual/combo therapy, Addition of vancomycin |
|
|
Term
|
Definition
| Ciprofloxacin 500-750 mg PO BID PLUS Amoxicillin/Clavulanate 500 mg PO q 8 hours |
|
|
Term
| Appropriate IV Monotherapy |
|
Definition
| Ceftazidime or Cefepime or Carbapenem (nort Ertapenem) or Piperacillin/tazobactam |
|
|
Term
| Appropriate Dual IV Therapy |
|
Definition
| Aminoglycoside PLUS zosyn OR Cefepime or ceftazidime OR carbapenem; Do Not combine 2 beta lactams |
|
|
Term
|
Definition
| Linezolid, Daptomycin, Ceftaroline |
|
|
Term
| not recommended as empiric antifungal therapy; does not cover Aspergillus spp and some candida spp |
|
Definition
|
|
Term
| drug of choice for Aspergillus spp; may consider when patient at risk for Aspergillus spp |
|
Definition
|
|
Term
| only echinocandin approved for use in NF; active against Candida and Aspergillus spp; similar to amph B in breakthrough fungal infection rates and fever resolution, but less drug toxicities and ADRs |
|
Definition
|
|
Term
| broad anti-fungal spectrum; lipid formulations preferred over conventional, less toxic, but more expensive |
|
Definition
|
|
Term
|
Definition
|
|
Term
| decrease febrile episodes/infections, may select for resistant gram-negative rods and MRSA |
|
Definition
|
|
Term
| decreased infection rates, but NOT mortality; ADR: bone marrow suppression, fungal overgrowth; not active vs Pseudomonas, may select out of resistance |
|
Definition
|
|
Term
|
Definition
| Azoles, Enchinocandins, Amphotericin |
|
|
Term
|
Definition
| fluconazole, voriconazole, posaconazole |
|
|
Term
|
Definition
|
|
